<DOC>
	<DOCNO>NCT02506465</DOCNO>
	<brief_summary>The study objective demonstrate efficacy safety Medi-Tate iTIND compare control group ( catheter ) .</brief_summary>
	<brief_title>Pivotal Study Assess Safety Effectiveness iTIND Device</brief_title>
	<detailed_description>Medi-Tate i-Temporary Implantable Nitinol Device ( iTIND ) intend treat subject symptomatic BPH . A total 150 subject symptomatic BPH enrol study , accord eligibility criterion . Study duration 12 month include 7 visit : screening , screen follow , implantation , retrieval , 6 week follow , 3 month follow 12 month follow . iTIND Device implant 5-7 day . Sham routine Foley catheter procedure .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . Subject sign informed consent form ( ICF ) 2 . Age 50 3 . Male symptomatic BPH . 4 . IPSS symptom severity score ≥ 10 5 . Peak urinary flow &lt; 12 ml/sec . Meeting criterion ( 2 ) two separate voiding trial , minimum void volume least 125 cc void trial . 6 . Prostate volume 25 ml 75 ml ( assess ultrasound ) 7 . Blood CBC biochemistry two week screen demonstrating : Normal value PT , PTT INR test ( anticoagulant stop accord GCP ) 8 . Subject able comply study protocol 9 . Normal Urinalysis urine culture 10 . Cardiac arrhythmia , cardiac disease include congestive heart failure , uncontrolled diabetes mellitus , significant respiratory disease , know immunosuppression ; 11 . Neurogenic bladder and/or sphincter abnormality due Parkinson 's disease , multiple sclerosis , cerebral vascular accident , diabetes 12 . A post void residual ( PVR ) volume &gt; 250 ml measure ultrasound acute urinary retention 13 . Compromised renal function ( i.e. , serum creatinine level &gt; 1.8 mg/dl , upper tract disease ) ; 14 . Confirmed suspected bladder cancer ; 15 . Recent ( within 3 month ) cystolithiasis hematuria ; 16 . Urethral stricture , bladder neck contracture , urinary bladder stone potentially confound bladder pathology ; 17 . An active urinary tract infection . 18 . Enrolled another treatment trial disease within past 30 day . 19 . Previous colo rectal surgery ( hemorrhoidectomy ) history rectal disease therapy may potentially cause injury site previous rectal surgery , e.g. , transrectal probe use ; 20 . Previous pelvic irradiation , cryosurgery radical pelvic surgery ; 21 . Previous prostate surgery , balloon dilatation , stent implantation , laser prostatectomy , hyperthermia , invasive treatment prostate 22 . History prostatitis within past 5 year . 23 . Median lobe obstruction prostate . 24 . Cancer consider cure , except basal cell squamous cell carcinoma skin ( cure define evidence cancer within past 5 year ) . 25 . Any serious medical condition likely impede successful completion study 26 . Participating investigational study either drug device influence collection valid data study . 27 . Subjects actively take medication affect urination BPH symptom complete require washout period . 28 . Baseline PSA ≥ 10 ng/ml . 29 . Positive DRE . 30 . Baseline PSA 2.510 ng/ml free PSA &lt; 25 % , without subsequent negative prostate biopsy .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>